Breaks Categories: News

WednesdayFeb 12, 2020 12:31 pm

NetworkNewsBreaks – Daré Bioscience, Inc. (NASDAQ: DARE) Featured in ROTH Equity Research Report

Daré Bioscience (NASDAQ: DARE) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “With DARE’s recent exclusive licensing deal with Bayer for Ovaprene totaling $310M in milestone payments (excluding double digit royalties) and a $20M payment after pivotal study completion, we will talk to Dr. Thurman, Associate Professor of OB/GYN and Director of Resident Research at EVMS, to figure out Ovaprene’s value proposition as a novel contraceptive. We will also discuss DARE-BV1's existing dataset and its clinical potential for the treatment of bacterial vaginosis (BV).” To request access to the full report,…

Continue Reading

WednesdayFeb 12, 2020 12:29 pm

NetworkNewsBreaks – Albireo Pharma, Inc. (NASDAQ: ALBO) Featured in ROTH Equity Research Report

Albireo Pharma (NASDAQ: ALBO) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Last Wednesday, ALBO announced a trio of key clinical updates across three different liver indications, with the most imminent being Ph3 readout for odevixibat in PFIC in mid 2020, followed by a pivotal trial in biliary atresia in 1H20 as well as a pivotal study in Alagille syndrome by YE20. See below for our thoughts below on why these clinical developments will make 2020 a fruitful year for ALBO.” To request access to the full report, visit http://nnw.fm/DXCr3 About…

Continue Reading

WednesdayFeb 12, 2020 12:24 pm

NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Featured in ROTH Equity Research Report

INmune Bio (NASDAQ: INMB) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Last week, we hosted INMB management meetings in New York and conclude that even early clinical success with any one of its programs would justify our valuation. We view INMB's DN-TNF platform to be a highly rational and safe approach to several diseases that are increasingly associated with surreptitious chronic inflammation. Earlier stage cancer therapy INKmune has advantages to other NK cell therapies including no removal of patient NK cells, a one size fits all approach, and substantially lower…

Continue Reading

WednesdayFeb 12, 2020 12:22 pm

NetworkNewsBreaks – Athersys Inc. (NASDAQ: ATHX) Featured in Dawson James Research Report

Athersys (NASDAQ: ATHX) was featured in a recent Institutional Research Report published by Dawson James Securities Inc. The report reads, “Acute respiratory distress syndrome (‘ARDS’) occurs when fluid builds up in the tiny, elastic air sacs (alveoli) in your lungs. Severe pneumonia, and the new Coronavirus too, can result in an infection in the lobes of the lungs, triggering an inflammatory cascade that causes death. Data on Athersys Multitem suggest efficacy in treating ARDS independent of the pathogen (or insult) that is the cause.” To request access to the full report, visit http://nnw.fm/2hKXg About Athersys Athersys is a biotechnology company…

Continue Reading

WednesdayFeb 12, 2020 11:20 am

NetworkNewsBreaks – Youngevity International Inc.’s (NASDAQ: YGYI) CLR Roaster’s Café La Rica Remains Official Cafecito of Miami Marlins

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments, including a commercial coffee enterprise and its newly acquired commercial hemp enterprise, today announced that its wholly-owned subsidiary CLR Roasters is continuing its successful partnership with Major League Baseball's Miami Marlins. According to the update, Café La Rica(R) Gourmet Espresso will continue as the Official Cafecito of the Marlins for all 2020 season home games. Café La Rica will be served on site at Marlins Park in the home opener on March 26 when the Marlins play the Philadelphia Phillies. “This partnership continues a great, long-standing…

Continue Reading

WednesdayFeb 12, 2020 11:12 am

NetworkNewsBreaks – Nightfood Holdings Inc. (NGTF) Discusses “Game-Changer” Opportunity in Pregnancy Market in Exclusive SmallCapVoice.com Interview

Nightfood Holdings (OTCQB: NGTF), the award-winning ice cream company addressing America’s $50 billion-dollar nighttime snacking problem, today announced that that its CEO is featured in a new audio interview on SmallCapVoice.com (http://nnw.fm/te9P9). According to the update, Nightfood CEO Sean Folkson called in to SmallCapVoice.com, Inc. to discuss the significant opportunity he sees for Nightfood ice cream as a solution for pregnancy cravings. With over three million pregnant women in the United States at any time, Nightfood believes it can secure a stronghold in the market segment, a demographic that, as Folkson described, is motivated to change and optimize their behavior.…

Continue Reading

WednesdayFeb 12, 2020 10:12 am

NetworkNewsBreaks – Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT) Regains Compliance with Nasdaq Continued Listing Standards

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), a producer, developer and operator of augmented reality interactive entertainment games, toys and educational materials in China, today announced its February 3, 2020, receipt of notification from The Nasdaq Stock Market LLC stating that the company has regained compliance with Nasdaq Listing Rule 5250(c)(2). The standards required that the company file with the Securities and Exchange Commission on a Report of Foreign Private Issuer on Form 6-K ("Form 6-K") an interim balance sheet and income statement as of the end of its most recently completed second quarter (June 30, 2019), and Nasdaq considers…

Continue Reading

WednesdayFeb 12, 2020 10:02 am

NetworkNewsBreaks – Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Implements New Operating Structure to Drive Efficiencies, Accelerate Profitable Growth

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) on Tuesday announced the implementation of a new operating structure, including staff reductions, to drive efficiencies and support long-term, profitable growth. As previously announced on January 6, 2020, Supreme Cannabis' leadership team is focused on achieving greater efficiencies and speed to market by rightsizing production, overhead and capital expenditures. “As Interim President and CEO, I committed to take immediate steps to position Supreme Cannabis for long-term success, including rightsizing the Company's cost structure and focusing our efforts on near-term revenue-generating opportunities,” Supreme Cannabis Director and Interim President and CEO Colin Moore…

Continue Reading

WednesdayFeb 12, 2020 9:22 am

NetworkNewsBreaks – Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) Providing Corporate Update via Conference Call on February 26

Australis Capital (CSE: AUSA) (OTC: AUSAF) on Tuesday announced that it will be hosting a live conference call at 1:00 PM EST on Wednesday, February 26, 2020 to provide a corporate update. Interested individuals may join the call by dialing 1.888.396.8064 for the Toll-Free North America line or 1.416.764.8649 for the Canada line. To view the full press release, visit http://nnw.fm/s5GrD About Australis Capital Inc. AUSA operates and builds transformative, differentiated cannabis companies predominantly in the United States, a highly regulated, fragmented, and rapidly expanding industry. AUSA adheres to stringent evaluation and operating criteria focusing on high-quality opportunities while maintaining…

Continue Reading

TuesdayFeb 11, 2020 1:40 pm

NetworkNewsBreaks – AVROBIO Inc. (NASDAQ: AVRO) Featured in Mizuho Securities Research Report

AVROBIO (NASDAQ: AVRO) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We are raising our PT on AVRO from $28 to $35 following positive clinical data updates yesterday at WORLDSymposium 2020 where we also attended the company's analyst event. Clinical data in Fabry continues to support a potential best-in-class gene therapy, and transition from academic process to AVRO's proprietary platform could offer additional clinical benefits. Initial data in Cystinosis was also positive, further supporting AVRO's gene therapy platform. Multiple data updates are expected throughout 2020, along with potential regulatory updates,…

Continue Reading